Joseph V Aufheimer, NP
Nurse Practitioner · Santa Rosa
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 5 years
- Graduated 2021
Offices
2 locations · Deepa Hasija MD · 8 clinicians in this group
Looking this up.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Joseph V Aufheimer’s office at (707) 780-2140 to ask if they take your plan before you enroll.
Original Medicare doctor bills
$4,773
Medicare paid this office $4,773 for 28 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 28 | $4,298 | $73 |
Who their Medicare patients are
28 Original Medicare patients in 2024. Average age 61 · Under 65 46% · 85 and older 0% · Women 54% · Also on Medicaid 50% · Health risk score 1.48. Above the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 75% · Depression 75% · Diabetes 43%.
The office billed $15,328, Medicare allowed $6,819 and paid $4,773; for 64 services of 3 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Medicaid work
$36,377 in 2024
Medicaid paid $36,377 for 589 billed services this clinician did in 2024, up to 58 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 589 | $36,377 |
| 2024 | 589 | 1 | 58 | $36,377 |
| 2023 | 172 | 1 | 22 | $9,845 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 172 | $9,845 |
Drugs they prescribed that Part D paid
$214,115
Pharmacies billed $214,115 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 902) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
861 generic and 41 brand-name prescriptions · $214,115 in drug cost · 62 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Rexulti | 16 | $22,900 | $1,431 |
| Aripiprazole | 31 | $4,887 | $158 |
| Quetiapine | 56 | $1,198 | $21 |
| Oxcarbazepine | 26 | $1,190 | $46 |
| Buspirone | 80 | $971 | $12 |
See all 24 drugs
| Rexulti | 16 | $22,900 | $1,431 |
| Aripiprazole | 31 | $4,887 | $158 |
| Quetiapine | 56 | $1,198 | $21 |
| Oxcarbazepine | 26 | $1,190 | $46 |
| Buspirone | 80 | $971 | $12 |
| Divalproex | 17 | $646 | $38 |
| Olanzapine | 15 | $404 | $27 |
| Trazodone | 82 | $383 | $5 |
| Duloxetine | 49 | $371 | $8 |
| Mirtazapine | 32 | $350 | $11 |
| Bupropion Hcl Sr | 37 | $336 | $9 |
| Hydroxyzine | 11 | $282 | $26 |
| Sertraline | 66 | $279 | $4 |
| Eszopiclone | 12 | $258 | $22 |
| Hydroxyzine Pamoate | 31 | $258 | $8 |
| Zolpidem | 28 | $245 | $9 |
| Gabapentin | 21 | $220 | $10 |
| Escitalopram | 34 | $199 | $6 |
| Prazosin | 19 | $188 | $10 |
| Alprazolam | 32 | $181 | $6 |
| Fluoxetine | 43 | $151 | $4 |
| Paroxetine | 15 | $116 | $8 |
| Lamotrigine | 12 | $69 | $6 |
| Clonazepam | 19 | $51 | $3 |
Year by year
| 2024 | 902 | 66 | 0% (0) | 5% | $214,115 |
| 2023 | 801 | 76 | 0% (0) | 4% | $113,613 |
| 2022 | 49 | 15 | 0% (0) | None | $2,653 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 25 drugs
| Quetiapine | 71 | $1,264 | $18 |
| Duloxetine | 34 | $1,087 | $32 |
| Lamotrigine Er | 12 | $855 | $71 |
| Oxcarbazepine | 14 | $749 | $53 |
| Aripiprazole | 23 | $576 | $25 |
| Gabapentin | 17 | $544 | $32 |
| Buspirone | 53 | $494 | $9 |
| Risperidone | 11 | $449 | $41 |
| Olanzapine | 18 | $399 | $22 |
| Escitalopram | 57 | $374 | $7 |
| Mirtazapine | 32 | $356 | $11 |
| Hydroxyzine Pamoate | 39 | $336 | $9 |
| Trazodone | 59 | $313 | $5 |
| Prazosin | 24 | $310 | $13 |
| Paroxetine | 20 | $196 | $10 |
| Sertraline | 24 | $181 | $8 |
| Temazepam | 16 | $169 | $11 |
| Lamotrigine | 25 | $168 | $7 |
| Alprazolam | 25 | $164 | $7 |
| Bupropion Hcl Sr | 14 | $157 | $11 |
| Bupropion Xl | 12 | $144 | $12 |
| Fluoxetine | 24 | $123 | $5 |
| Benztropine Mesylate | 14 | $109 | $8 |
| Zolpidem | 21 | $106 | $5 |
| Clonazepam | 16 | $84 | $5 |
Money from drug and device companies
$295 in 2025
| 2025 | 3 | 9 | None | $295 |
| 2024 | 12 | 72 | None | $1,872 |
| 2023 | 21 | 100 | None | $2,566 |
| 2022 | 12 | 16 | None | $293 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| E.R. Squibb & Sons L.L.C. | Cobenfy | $224 | 6 payments
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $47 | 2 payments
|
| Abbvie | Vraylar | $24 | 1 payment
|
See all 9 published payments
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-13 | Cobenfy | $32 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-10 | Cobenfy | $20 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-06-24 | Cobenfy | $18 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-06-11 | Cobenfy | $26 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-22 | Cobenfy | $7 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-05-16 | Caplyta | $32 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-13 | Cobenfy | $121 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-04-11 | Caplyta | $15 |
| Abbvie | Meals · 2025-04-09 | Vraylar | $24 |
See earlier years (2024, 2023, 2022)
2024: $1,872
| Abbvie | Vraylar | $469 | 16 payments
|
| Alkermes | Aristada | $286 | 10 payments
|
| Otsuka America Pharmaceutical | Rexulti | $255 | 9 payments
|
| Janssen Pharmaceuticals | Invega Sustenna | $245 | 14 payments
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $185 | 5 payments
|
| Corium | Azstarys | $108 | 6 payments
|
| Neurocrine Biosciences | Ingrezza | $93 | 3 payments
|
| Almatica Pharma | Loreev Xr | $92 | 5 payments
|
| Supernus Pharmaceuticals | Qelbree | $56 | 1 payment
|
| Lilly USA | Mounjaro | $34 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $29 | 1 payment
|
| Lundbeck | Rexulti | $18 | 1 payment
|
2023: $2,566
| Abbvie | Vraylar | $536 | 16 payments
|
| Otsuka America Pharmaceutical | Rexulti | $408 | 14 payments
|
| Janssen Pharmaceuticals | Spravato | $390 | 16 payments
|
| Iti | Caplyta | $245 | 8 payments
|
| Idorsia Pharmaceuticals US | Quviviq | $221 | 9 payments
|
| Lundbeck | Rexulti | $145 | 7 payments
|
| Alkermes | Aristada | $125 | 6 payments
|
| Neurocrine Biosciences | Ingrezza | $107 | 4 payments
|
| Xeris Pharmaceuticals | Gvoke Hypopen | $66 | 4 payments
|
| Axsome Therapeutics | Auvelity | $65 | 3 payments
|
| Brainsway USA | None | $49 | 1 payment
|
| MannKind | Afrezza | $34 | 2 payments
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $31 | 2 payments
|
| Merck Sharp & Dohme | Januvia | $30 | 1 payment
|
| Teva Pharmaceuticals USA | Uzedy | $23 | 1 payment
|
| Novo Nordisk | None | $20 | 1 payment
|
| Insulet | Omnipod | $17 | 1 payment
|
| Kyowa Kirin | Crysvita | $16 | 1 payment
|
| Supernus Pharmaceuticals | Qelbree | $14 | 1 payment
|
| Athena Bioscience | Nexiclon Xr | $13 | 1 payment
|
| Corium | Azstarys | $12 | 1 payment
|
2022: $293
| Janssen Pharmaceuticals | Spravato | $50 | 2 payments
|
| Avanir Pharmaceuticals | Nuedexta | $41 | 2 payments
|
| Supernus Pharmaceuticals | Qelbree | $40 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $25 | 1 payment
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $21 | 1 payment
|
| Idorsia Pharmaceuticals US | Quviviq | $19 | 1 payment
|
| Abbvie | Vraylar | $19 | 1 payment
|
| Neurocrine Biosciences | Ingrezza | $18 | 1 payment
|
| Mannkind | Afrezza | $17 | 1 payment
|
| Indivior | Perseris | $15 | 1 payment
|
| Lundbeck | Rexulti | $15 | 1 payment
|
| Lilly USA | Mounjaro | $14 | 1 payment
|
Professional record
- NPI
- 1538892054
- Licence
- NV 855418
- Group
- Deepa Hasija MD
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 363LP0808X (363LP0808X)
- Mailing address
- 2600 Center St Ne, Salem, OR, 97301
- NPI first listed
- 2022-07-01
- NPI last updated
- 2026-07-09
- NPI record certified
- 2026-07-09
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 5105 Camino Al Norte Ste 100, North Las Vegas, NV, 89031